European Pharmaceutical Review
SEPTEMBER 30, 2022
Professor Hongsoo Choi’s team at The Department of Robotics and Mechatronics Engineering at the Daegu Gyeongbuk Institute of Science & Technology (DGIST), Korea, developed revolutionary technology that produces over 100 microrobots per minute. The collaboration with Professor Sung-Won Kim’s team at Seoul St. Mary’s Hospital, Catholic University of Korea and Professor Bradley J.
pharmaphorum
SEPTEMBER 28, 2022
The US FDA’s Center for Devices and Radiological Health (CDRH) dropped a bevy of new digital health guidances and reports today and yesterday, providing some long-awaited clarity and peeks into the agency’s future plans. . The Pre-Cert pilot report. The push started yesterday with the 31-page key findings report from the FDA Pre-Certification Program pilot.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 27, 2022
Prime Medicine likens its gene-editing technology to a word processor that searches for the correct place in the genome to make an edit, replacing or repairing a wide variety of target DNA. The preclinical biotech is now spelling out its future plans with the letters I-P-O.
Dominic Tyer
SEPTEMBER 30, 2022
Pharmaceutical companies with a chief marketing officer are thin on the ground, but their number will shortly see a slight increase thanks to a new appointment at Pfizer
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Medical Device Success
SEPTEMBER 27, 2022
Reading time: 2 – 4 minutes. Fact is, women have more challenges in pursuing their careers than men. In the show notes you will find a link to the McKinsey 2021 report on Women in the Workplace that clearly spells this out. To address these challenges, Shelly O’Donovan, CEO, Authentic Influence Group is creating a Life Science Women’s Mastermind group in the MedTech Leaders community.
Pharmaceutical Technology
SEPTEMBER 30, 2022
After several setbacks, bluebird bio bounces back with two major FDA gene therapy approvals. Last month, Zynteglo (betibeglogene autotemcel), or beti-cel, was approved as a one-time potentially curative gene therapy for patients with beta-thalassaemia who require regular blood transfusions. Shortly after this, the FDA announced the accelerated approval of bluebird's Skysona (elivaldogene autotemcel), or eli-cel, on 19 September.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
SEPTEMBER 26, 2022
The study will focus on checkpoint inhibitor refractory non-small cell lung cancer
pharmaphorum
SEPTEMBER 27, 2022
While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. Seagen is paying $50 million upfront for global rights to the programme, a bispecific T cell engager intended as a treatment for EGFR-positive solid tumours, with another $650 million at the back end in milestone payments.
PM360
SEPTEMBER 28, 2022
For life sciences commercial teams, effectively engaging physicians and supporting them with education on the evolving science around products and conditions requires a deep understanding of physician content needs and channel preferences. These are dynamic factors, playing out differently across specialty groups and stages of the patient journey, as well as the condition being treated.
MedCity News
SEPTEMBER 27, 2022
Chronic conditions cause medical debt in U.S. households across all income levels, according to a new report. Medical debt has frequently been associated with cancer and, more recently, diabetes treatment, but there are other chronic conditions that contribute significantly to medical bills — such as heart disease, asthma, anxiety and lung disease.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
SEPTEMBER 29, 2022
Results show reduction of clinical decline in global study of people with Alzheimer's Disease
Medgadget
SEPTEMBER 26, 2022
Scientists at the University of New South Wales in Australia have developed a method to produce human blood stem cell precursors from human pluripotent stem cells. The method may have use in treating cancer patients who require high doses of such blood stem cells to help replenish endogenous populations that have been destroyed by chemotherapy. The researchers exploited the tendency of cells to respond to mechanical stimuli and cultured the pluripotent stem cells in a microfluidic device that mi
pharmaphorum
SEPTEMBER 30, 2022
Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the middle of 2023. Roche-partnered SRP-9001 (delandistrogene moxeparvovec) has been submitted for approval to treat ambulatory (walking) patients with DMD, a genetic disorder characterised by progressive muscle degeneration due to alterations in a protein called dystrophin that helps keep muscle cells intact.
MedCity News
SEPTEMBER 27, 2022
If single use devices are inevitable, the next step after “why” needs to be an understanding of “how” medtech companies and device makers can get on the right side of the movement.
PharmaTimes
SEPTEMBER 28, 2022
Phase 1b study evaluates effects of sevuparin on the symptoms of volunteer participants
European Pharmaceutical Review
SEPTEMBER 29, 2022
According to a new report , implementing a Transferable Exclusivity Extension (TEE) system could solve the “broken economic model” for researching and developing new antibiotics in Europe. As the threat of antimicrobial resistance (AMR), sometimes called the hidden or silent pandemic , grows, new and novel antibiotics are needed to combat infections becoming more resistant to current treatments.
pharmaphorum
SEPTEMBER 29, 2022
Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer’s disease with a claim that their new drug lecanemab showed a “highly statistically significant” reduction in clinical decline in a phase 3 trial. The highly-anticipated readout from the Clarity AD has shown that lecanemab met primary and secondary endpoints in patients with early-stage Alzheimer’s, said the two companies in a joint statement – although for now only the
MedCity News
SEPTEMBER 27, 2022
Among CVS Health’s adult members, there was a 34.1% decrease in suicide attempts in 2022, compared to 2019. However, there was a 32% increase among adolescents, largely due to challenges from Covid-19. In response, CVS Health is expanding its resources with new initiatives that focus on adolescents.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
SEPTEMBER 28, 2022
Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.
PM360
SEPTEMBER 28, 2022
Market access stands at the cusp of a golden opportunity to help increase healthcare efficiency, improve outcomes, and transform the patient experience—but only if we’re brave enough to recalibrate our approach. For years, pharma’s engagement with payers has focused narrowly on securing access to treatments, with authorization and reimbursement our single-minded pursuit.
pharmaphorum
SEPTEMBER 27, 2022
Five wearable devices that monitor patients with Parkinson’s disease as they go about their lives have been given a provisional recommendation from NICE, making them available via the NHS while additional data is collected. The UK health technology assessment (HTA) organisation said the devices may be more accurate at making a clinical assessment of a patient’s symptoms and disease progression compared to intermittent, in-person appointments at the clinic.
MedCity News
SEPTEMBER 29, 2022
While some areas in the mental health tech space have been effective, some areas need improvement, experts said at MedCity’s Invest Digital Health conference. Providing digital mental health care can be difficult do in a cost-effective way, and many clinicians are wary of adopting technology in their practices.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
SEPTEMBER 28, 2022
In a study published in the Microchemical Journal , investigators outlined the development and validation of a HPLC-MS/MS (high-performance liquid chromatography-mass spectrometry) for the determination and quantification of N -nitrosodimethylamine (NDMA) in olmesartan medoxomil. The method was able to detect, separate and quantify NDMA in the active pharmaceutical ingredient (API), manufactured tablets and marketed tablets.
PharmaTimes
SEPTEMBER 29, 2022
Positive results in COVID-19 therapy phase 3 trials show effectiveness against five symptoms
pharmaphorum
SEPTEMBER 26, 2022
Social health—the dynamic, real-time action people take to find meaningful connections and share information that impact the health journey—has dramatically shifted the ways in which healthcare marketers can, and should, reach their desired audiences. . Through Health Union’s unique and expansive Social Health Network of more than 100,000 patient leaders; and millions of engaged patients and caregivers across a growing portfolio of more than 40 condition specific online health communities, this
MedCity News
SEPTEMBER 29, 2022
The patient financial experience in the U.S. is poor — patients have a hard time understanding pricing data and they often face exorbitant prices for care and medications. This problem will only get better if the healthcare industry rids itself of price-gouging middlemen and closed-door price negotiations held by businesspeople, according to a recent healthcare innovation panel.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
SEPTEMBER 29, 2022
Brii Biosciences , a multi-national drug development company, has published top-line results from a Phase I study evaluating its long-acting, single-dose, intramuscularly injected drug BRII-296 in postpartum depression (PPD). “We are encouraged by the possibility of providing a novel treatment option to the 900,000 people in the US affected by postpartum depression each year in which the current standard of care is suboptimal, often requiring hospitalisation, repeat therapy and daily doses of tr
Copyright Clearance Center
SEPTEMBER 30, 2022
The post CCC Launches OA Agreement Intelligence appeared first on Copyright Clearance Center.
pharmaphorum
SEPTEMBER 24, 2022
Imagine visiting your doctor’s office. Instead of swiping a co-pay card and filling out a paper form by hand, the receptionist says, “Please bring your phone closer. We take Apple Health here.” You wave your iPhone over a digital kiosk, instantly uploading your current medical record and insurance information. Your co-pay is then deducted from a Health Savings Account.
MedCity News
SEPTEMBER 29, 2022
Eisai Alzheimer’s disease drug candidate lecanemab now has data from a pivotal study showing a statistically significant reduction in cognitive decline. Lecanemab is already under FDA review for potential accelerated approval but the agency has said that results from this larger study could support full approval of the antibody drug.
Expert insights. Personalized for you.
136 
Let's personalize your content